Genprex presents positive preclinical data on Reqorsa Gene Therapy

Genprex (GNPX) announced that its research collaborators presented positive preclinical data for Reqorsa Gene Therapy for the treatment of ALK-EML4 positive non-small cell lung cancer. The data were presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which took place October 22-26, 2025 at the Hynes Convention Center in Boston. “The preclinical data presented at AACR-NCI-EORTC reinforces our oncology program strategy that reintroduces tumor suppressor genes to target cancer cells,” said Ryan Confer, President and Chief Executive Officer at Genprex. “These data also add to the existing preclinical data showing that REQORSA has significant activity on its own as well as when combined with other therapies in a mouse xenograft model with ALK-EML4 rearrangement. The combination of REQORSA and an ALK inhibitor led to longer survival in the mouse model. ALK-EML4 rearrangements occur in approximately 4% of all patients with NSCLC. We believe these positive data open a pathway for a potential future clinical trial in ALK-positive lung cancer.”